Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

42.19 0.41 +0.98%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:06 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 41 added · 38 removed · 158 modified; 52 with only figures updated; 3 moved without change